Volumen: 21 # Number : XXIII Congreso Argentino de Hematología
Publication Date : Noviembre Year: 2017
SIMPOSIO CONJUNTO
EHA-SAH |
Risk-adapted standard treatment
of myelodysplastic syndromes
Authors: Hellström-Lindberg E, Tobiasson M, Jädersten M
Abstract: Treatment of MDS has since many years been based
mainly on conventional risk scores dividing patients
into lower and higher-risk MDS. During recent years
the fast development of knowledge about mutational
profiles has added significantly to the decisionmaking
and has also fostered development of novel
targeted drugs in myeloid malignancies. Moreover,
the possibilities to guide patients through the hitherto
only curative therapeutic option, allogeneic stem cell
transplantation, have improved markedly. Hence
NGS sequencing is today affecting diagnostics,
prognostication, and choice of treatment, as well as
the tools for detection of minimal residual disease,
and will develop to a natural part of future patient
management.
Key words: MDS,
treatment,
mutations.
Pages :
|
